CASI Pharmaceuticals, Inc. Research And Development Expense

Quick Answer

CASI Pharmaceuticals, Inc. reported Research And Development Expense of $8.92 million for the year ending 2024.

  • CASI Pharmaceuticals, Inc. showed a decrease of -9.6% in Research And Development Expense from 2023 to 2024.
  • This data is from CASI Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
  • XBRL data for this metric is available from 2022 to 2024 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 3 years of available data (2022 to 2024), CASI Pharmaceuticals, Inc.'s Research And Development Expense has declined by 44.3%.
  • Historical annual values: Fiscal year 2024: $8.92 million | Fiscal year 2023: $9.86 million | Fiscal year 2022: $16.00 million.
  • Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: